Mon, 16 May 2016
After a very difficult first quarter, it’s time to reevaluate the online marketplace model. On this Financials edition of The Motley Fool’s Industry Focus podcast, host Gaby Lapera and analyst Jay Jenkins go beyond the headlines in their discussion to explain why these problems are much more than a short term speed bump. How did these companies get to this low point? What will it take for them to turn it around? Is it ever a good idea to make puns about something as boring as banking? To find out the answers to these questions and more, listen now. |
Fri, 13 May 2016
Inspired by a Seinfeld clip, we dive into the topic of write-offs and the different forms they take. A special thanks to Audible for supporting our podcast. Listeners can get a free 30 day trial at audible.com/fool. |
Thu, 12 May 2016
Tesla’s sky high valuation prices the company for perfection; is this warranted or should investors beware? |
Wed, 11 May 2016
GlaxoSmithKline takes on Pfizer and Biogen battles Celgene in this healthcare edition of Industry Focus. |
Tue, 10 May 2016
Big changes are happening in the world of entertainment and coffee consumption, here’s how investors can position their portfolios. |
Mon, 9 May 2016
There's reason to believe that they will. It's been nearly eight years since the financial crisis, yet Bank of America (NYSE: BAC) is still earning half as much money as it should be given its size. In this episode of Industry Focus: Financials, The Motley Fool's Gaby Lapera and John Maxfield discuss the role that Bank of America's 2008 purchase of Merrill Lynch plays in its subpar profitability. Thanks to Audible for supporting this episode. Get a free 30-day trial at audible.com/fool. |
Fri, 6 May 2016
We discuss stock splits, the strategy behind them, and why Facebook announced they were using C shares to offer investors a 3-to-1 split. |
Thu, 5 May 2016
If Tesla Motors plans for growth and its new Model 3 weren't ambitious enough, it now wants to make it all happen by 2018. Plus, earnings from Royal Dutch Shell, BHP Billiton & Vale's nightmare situation, and we dip into the mailbag.
|
Wed, 4 May 2016
Healthcare: Digging Into Disappointment. What Investors Need To Know About Sarepta and Gilead Sciences' "Bad News"
Discussing the details behind the FDA's negative vote on Sarepta's DMD drug and Gilead Sciences' sliding hepatitis C sales. |
Tue, 3 May 2016
At $3.8 billion, Dreamworks founder and CEO Jeffrey Katzenberg called the buyout “the deal I’d always hoped would come along.” But after a major restructuring and string of box office disappointments for the animation studio, is Comcast getting its money’s worth? |